Petros Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2018
Net Income	1.91	-14.32	-8.16	-20.04	-8.99	Upgrade
Depreciation & Amortization	-	-	3.42	5.72	6.88	Upgrade
Other Amortization	-	-	-	-	0.01	Upgrade
Loss (Gain) From Sale of Assets	-6.97	-	-	-	-	Upgrade
Asset Writedown & Restructuring Costs	-	-	-	7.46	-	Upgrade
Stock-Based Compensation	0.3	0.47	0.42	1.2	1.31	Upgrade
Provision & Write-off of Bad Debts	-	-	0.03	-0.17	0.15	Upgrade
Other Operating Activities	0.68	10.06	-3.95	-3.87	-9.46	Upgrade
Change in Accounts Receivable	-	-	-0.14	0.52	2.55	Upgrade
Change in Inventory	-	-	-0.91	-0.84	0.41	Upgrade
Change in Accounts Payable	-0.68	0.35	-0.09	-2.75	-1.05	Upgrade
Change in Unearned Revenue	-	-	-0.16	0.21	-	Upgrade
Change in Other Net Operating Assets	0.02	-0.62	1.94	-0.23	-3.67	Upgrade
Operating Cash Flow	-6.73	-2.6	-7.63	-12.8	-11.86	Upgrade
Other Investing Activities	-	-0.02	-	-	-	Upgrade
Investing Cash Flow	-	-0.02	-	-	-	Upgrade
Long-Term Debt Repaid	-	-	-1.46	-1.62	-7.19	Upgrade
Net Debt Issued (Repaid)	-	-	-1.46	-1.62	-7.19	Upgrade
Issuance of Common Stock	8.5	-	15	-	25.76	Upgrade
Other Financing Activities	-	-0.77	-	-	-	Upgrade
Financing Cash Flow	8.16	-7	11.54	-1.62	18.57	Upgrade
Net Cash Flow	1.43	-9.63	3.91	-14.42	6.71	Upgrade
Free Cash Flow	-6.73	-2.6	-7.63	-12.8	-11.86	Upgrade
Free Cash Flow Margin	-	-	-130.99%	-213.57%	-151.86%	Upgrade
Free Cash Flow Per Share	-0.24	-8.11	-87.62	-154.54	-272.32	Upgrade
Cash Interest Paid	-	-	0.54	0.6	0.42	Upgrade
Levered Free Cash Flow	-12.78	7.59	-1.39	-26.93	-5	Upgrade
Unlevered Free Cash Flow	-12.78	7.59	-1.05	-26.56	-4.78	Upgrade
Change in Working Capital	-0.66	-0.27	0.62	-3.09	-1.76	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.